| train (N=92) |
validation (N=102) |
TRUE (N=194) |
P-value | |
|---|---|---|---|---|
| Age(years) | ||||
| Mean (SD) | 63.3 (7.91) | 64.1 (8.33) | 63.7 (8.12) | 1 |
| Median [Min, Max] | 64.5 [35.0, 76.0] | 66.0 [33.0, 80.0] | 65.0 [33.0, 80.0] | |
| Sex | ||||
| FeMale | 10 (10.9%) | 11 (10.8%) | 21 (10.8%) | 1 |
| Male | 82 (89.1%) | 91 (89.2%) | 173 (89.2%) | |
| Smoking | ||||
| No | 16 (17.4%) | 32 (31.4%) | 48 (24.7%) | 0.0789 |
| Yes | 76 (82.6%) | 70 (68.6%) | 146 (75.3%) | |
| Pathologic subtype | ||||
| Non squamous | 48 (52.2%) | 58 (56.9%) | 106 (54.6%) | 0.807 |
| Squamous | 44 (47.8%) | 44 (43.1%) | 88 (45.4%) | |
| PFS(months) | ||||
| Mean (SD) | 15.3 (10.6) | 13.4 (6.44) | 14.3 (8.68) | 1 |
| Median [Min, Max] | 12.5 [0.600, 37.4] | 13.1 [0.367, 27.9] | 12.7 [0.367, 37.4] | |
| OS(months) | ||||
| Mean (SD) | 20.7 (10.7) | 14.5 (6.47) | 17.4 (9.26) | 1 |
| Median [Min, Max] | 20.9 [1.33, 39.3] | 14.8 [0.367, 27.9] | 16.5 [0.367, 39.3] | |
| PD-L1 TPS group | ||||
| <1% | 11 (12.0%) | 9 (8.8%) | 20 (10.3%) | 0.93 |
| 1-50% | 19 (20.7%) | 16 (15.7%) | 35 (18.0%) | |
| >=50% | 12 (13.0%) | 18 (17.6%) | 30 (15.5%) | |
| Missing | 50 (54.3%) | 59 (57.8%) | 109 (56.2%) | |
| Clinical benefit | ||||
| DCB | 69 (75.0%) | 89 (87.3%) | 158 (81.4%) | 0.165 |
| NDB | 23 (25.0%) | 12 (11.8%) | 35 (18.0%) | |
| Unknown | 0 (0%) | 1 (1.0%) | 1 (0.5%) | |
| LDH | ||||
| Mean (SD) | 241 (160) | 242 (189) | 241 (175) | 1 |
| Median [Min, Max] | 189 [66.7, 1110] | 193 [96.0, 1660] | 190 [66.7, 1660] | |
| Missing | 1 (1.1%) | 5 (4.9%) | 6 (3.1%) | |
| NLR | ||||
| Mean (SD) | 3.84 (2.05) | 4.05 (2.74) | 3.95 (2.43) | 1 |
| Median [Min, Max] | 3.37 [1.04, 9.80] | 3.30 [1.15, 16.3] | 3.32 [1.04, 16.3] | |
| Missing | 0 (0%) | 2 (2.0%) | 2 (1.0%) | |
| Bone metastasis | ||||
| No | 59 (64.1%) | 51 (50.0%) | 110 (56.7%) | 0.14 |
| Yes | 33 (35.9%) | 51 (50.0%) | 84 (43.3%) | |
| Brain metastasis | ||||
| No | 76 (82.6%) | 86 (84.3%) | 162 (83.5%) | 0.95 |
| Yes | 16 (17.4%) | 16 (15.7%) | 32 (16.5%) | |
| Liver metastasis | ||||
| No | 84 (91.3%) | 83 (81.4%) | 167 (86.1%) | 0.137 |
| Yes | 8 (8.7%) | 19 (18.6%) | 27 (13.9%) | |
| Pleura metastasis | ||||
| No | 69 (75.0%) | 71 (69.6%) | 140 (72.2%) | 0.705 |
| Yes | 23 (25.0%) | 31 (30.4%) | 54 (27.8%) | |
| Lymph metastasis | ||||
| No | 46 (50.0%) | 36 (35.3%) | 82 (42.3%) | 0.117 |
| Yes | 46 (50.0%) | 66 (64.7%) | 112 (57.7%) |